Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Personalized Nutrition Market - Outlook and Forecast 2023-2028
The global parenteral nutrition market surpassed USD 7.18 billion in 2021 and is projected to reach USD 10.70 billion by 2027, growing at a CAGR of 6.88% during the forecast period. The increasing global poverty rate and concerns about nutritional health are the primary factors driving the demand for parenteral nutrition supply. Malnutrition, particularly among hospitalized patients, is a growing concern that necessitates the use of parenteral nutrition. The key target populations for parenteral nutrition include hospitalized patients, preterm infants, cancer patients, and individuals with other diseases that require nutritional support, contributing to the growth of the global market.
Parenteral nutrition, also known as intravenous nutrition, involves the administration of nutrients such as carbohydrates, proteins, fats, electrolytes, minerals, vitamins, water, and trace elements via intravenous infusion. It is used to provide nutritional support to patients who are unable to tolerate enteral or oral nutrition delivery. There are two types of parenteral nutrition: total parenteral nutrition (TPN) and partial parenteral nutrition (PPN). The choice between TPN and PPN depends on the patient’s condition and nutritional status.
|No. of Pages||
USD 7.2 billion in 2021
Nutrients, Indication, Patient Group, End-user, and Geography
|No. of Companies Mentioned||
The global parenteral nutrition market is primarily driven by increasing concerns about nutritional health due to changes in people’s lifestyles, the growing need for nutritional support to maintain a healthy life, and economic, social, and environmental factors. Furthermore, the market is experiencing rapid growth due to innovations and advancements. Market players are pursuing inorganic growth strategies, such as partnerships and collaborations, to enhance their medical nutrition offerings. For example, in 2020, Baxter International, a leading player in clinical nutrition, formed a joint venture with VIPUN Medical, a pioneer in technology development. This collaboration aimed to improve the medical nutrition segment by commercializing the VIPUN gastric monitoring system for patients intolerant to enteral nutrition. Baxter’s parenteral nutrition products are designed to meet patients’ nutritional needs.
Personalized and commercially available medicine has become a growing trend in the healthcare industry. The preference for standardized and commercial parenteral nutrition solutions is on the rise, reshaping the parenteral nutrition market. Standardized products offer convenience and flexibility to healthcare providers as they can be administered to patients without the need for in-house compounding. These products can be sourced as institution-specific formulations, patient-specific customized solutions, or commercially available products. The demand for standardized and commercial parenteral nutrition has been increasing due to the associated benefits, such as stability, compatibility, and minimal manipulation.
Parenteral nutrition plays a crucial role in the treatment and management of various chronic conditions, malnourished patient populations, and emergency medical conditions. The global increase in patient population drives the demand for nutritional support in healthcare settings such as hospitals, clinics, and home care. The prevalence of chronic conditions worldwide significantly contributes to the demand for hospitalization and the need for nutritional support among these patients who are unable to meet their nutritional needs. Moreover, the impact of poverty on health has led to various medical conditions and increased demand for parenteral nutrition.
Cancer is a leading cause of death worldwide, with over 18 million cases reported in 2020. Malnutrition is a common condition among cancer patients and requires external nutritional support. In fact, malnutrition contributes to the deaths of approximately 1.8 million people with cancer. The high prevalence of malnutrition among cancer patients drives the growth of the parenteral nutrition market.
Parenteral nutrition is a complex procedure that provides external nutritional support to patients. Hospitalized patients often receive parenteral nutrition due to malnutrition associated with their medical condition. However, there are challenges in delivering parenteral nutrition, including the failure to achieve desired goals due to inadequate monitoring. Compared to enteral nutrition, parenteral nutrition receives less emphasis, partly due to the higher risk of complications. The main concerns associated with parenteral nutrition include bloodstream infections, digestive tract atrophy when not in use, and intravenous catheter-related complications.
The market is segmented based on various factors, including nutrients, indication, patient group, end-user, and geography.
Segmentation by Nutrients
Segmentation by Indication
Segmentation by Patient Group
Pediatric Patient Group
Adult Patient Group
Segmentation by End-users
Ambulatory Care Settings
Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey
The global parenteral nutrition market is divided into three nutrient categories: macronutrients, automated compounds, and micronutrients. In 2021, the macronutrient segment held a higher market share of 66.65% and dominated the other segments. Macronutrients, such as lipids and amino acids, are essential ingredients in parenteral nutrition solutions. They provide energy, support bodily functions, and rapidly improve physical well-being. Manufacturers and market players offer a wide range of products based on macronutrients, further driving the growth of this segment.
The automated compounds segment of the global parenteral nutrition market was valued at USD 1.35 billion in 2021. Automated compounding has gained popularity, particularly in pediatric parenteral nutrition. Volumetric pump systems are used to automate the process of parenteral nutrition compounding in major hospitals and healthcare settings. In the US, over 65% of hospitals rely on automated compounding devices.
Patient types in the parenteral nutrition market are categorized as pediatric and adult. The pediatric segment holds a major market share of 55.05% and is expected to dominate during the forecast period. The demand for parenteral nutrition supply among pediatric patients is fueled by factors such as a significant number of preterm patients, concerns about low birth weight, and malnutrition. Advances in trace elements and new products for pediatric parenteral nutrition also contribute to the growth of this segment.
The global parenteral nutrition market is further segmented into short-term and long-term indications. The short-term segment currently dominates the market with a 55.41% share. The increasing prevalence of conditions such as cancer, metabolic disorders, gut failure, and malnutrition globally drives the demand for healthcare services and the need for parenteral nutrition.
In terms of long-term indication, the global parenteral nutrition market was valued at USD 3.20 billion in 2021. Long-term parenteral nutrition is a crucial medical nutrition therapy delivered intravenously over an extended period based on patient requirements. Gastrointestinal disorders and the impact of medications and treatments on the digestive system drive the demand for long-term parenteral nutrition. Recovery from digestive system injuries or surgeries takes significant time, leading to a high demand for long-term parenteral nutrition supply.
Hospitals dominate the end-user segment of the parenteral nutrition market, accounting for a 47.57% share in 2021. Factors such as malnutrition, diseases-related malnutrition, and hospital-associated malnutrition conditions contribute significantly to the demand for parenteral nutrition in hospitals. Hospitals provide primary and well-established infrastructure for patients requiring longer stays due to medical conditions or procedures. According to Baxter, one of the industry leaders, approximately 2 million hospitals in the US are affected by malnutrition prevalence.
The global parenteral nutrition market in ambulatory care settings was valued at USD 3.13 billion in 2021. This segment includes clinics and external healthcare services. In developing countries or emerging markets, malnutrition imposes a significant cost burden on patients. To avoid long hospital stays, patients prefer other healthcare settings such as clinics and ambulatory care settings. These settings play a vital role in delivering parenteral nutrition, particularly for patients suffering from chronic illnesses. The high cost burden associated with hospital settings and longer stays have led to a shift in patient preference towards ambulatory care settings.
North America dominates the global parenteral nutrition market with a market share of 41.05%. Factors driving industry growth in the region include high research expenditure by companies, government authorities, and private entities in the nutrition sector. This gives the region significant access to parenteral nutrition services. Additionally, the high healthcare expenditure and acceptance of home parenteral and other nutrition therapies in the US contribute to the anticipated growth of the parenteral nutrition market in the region.
The parenteral nutrition market in the Asia-Pacific (APAC) region was valued at USD 2.09 billion in 2021. The region is experiencing growth in the parenteral nutrition market due to factors such as an increasingly aging population, research and development in clinical nutrition, and the growth of regional healthcare infrastructure. The high prevalence of chronic disorders, including cancer, diabetes, gastrointestinal disorders, kidney failure, and cardiovascular diseases, further drives the demand for parenteral nutrition services in the region.
The European parenteral nutrition market is growing at a compound annual growth rate (CAGR) of 6.38% during the forecast period. The region’s parenteral nutrition market shows rapid progressive growth, fueled by the increasing influence of industry players, heightened focus on parenteral nutrition deliveries by government and healthcare authorities, and a stable economy. The European Society for Clinical Nutrition and Metabolism (ESPEN) plays a leading role in promoting basic research, advanced education, and awareness about clinical care and quality control in the field of parenteral and enteral nutrition.
Baxter, B. Braun Melsungen, Fresenius Kabi, JW Pharmaceuticals, and Kelun Pharmaceuticals are prominent players in the parenteral nutrition market. These companies hold significant market shares and demonstrate strong industry presence by providing advanced and high-quality solutions. Simultaneously, emerging industry players and start-ups aim to establish a strong customer base and expand their market reach. The presence of these emerging players positively impacts competition in the global parenteral nutrition market. The primary competition among industry players arises from new product launches and the introduction of emerging and gold standard formulations.
B. Braun Melsungen is a leading player in the global parenteral nutrition market. Conversely, Fresenius Kabi specializes in both parenteral nutrition (administered intravenously) and enteral nutrition (administered via tube feed, sip, or the gastrointestinal tract). Baxter is a key supplier of essential ingredients necessary for the development of well-balanced formulations in parenteral nutrition regimens. The company offers accessible and innovative solutions and services designed for use in various healthcare environments, including hospitals, ICUs, clinics, nursing homes, and home care settings within the parenteral nutrition market. Furthermore, Baxter supplies crucial ingredients for the development of well-balanced medical nutrition regimens.
Key companies profiled in this report include Baxter, B. Braun Melsungen, Fresenius Kabi, JW Pharmaceuticals, Sichuan Kelun Pharmaceuticals, Aculife, Albert David, Amanta Healthcare, American Reagent, BML PARENTERAL DRUGS, Caritas Healthcare, Eurofarma, EuroLife Healthcare Pvt. Ltd., Farmoterapica, Grifol, ICU Medical, Otsuka Pharmaceutical, Soleo Health, REVIV, Pfizer, Vifor Pharma.
Key Questions Answered
What is the current size of the parenteral nutrition market?
The parenteral nutrition market had a global size of USD 7.18 billion in 2021 and is projected to reach USD 10.70 billion by 2027.
What is the expected growth rate of the global parenteral nutrition market?
The global parenteral nutrition market is anticipated to grow at a compound annual growth rate (CAGR) of 6.88% from 2021 to 2027.
Which region holds the largest market share in the global parenteral nutrition market?
In 2021, the North American region held a significant market share of 41.05% in the parenteral nutrition market, surpassing other regions. This dominance is attributed to factors such as increased research and development in parenteral nutrition solutions, associated investments, and substantial governmental initiatives addressing malnutrition concerns, thereby providing greater access to parenteral nutrition services in the region.
Who are the major players in the global parenteral nutrition market?
The key players in the global parenteral nutrition market include Baxter, B. Braun Melsungen, Fresenius Kabi, JW Pharmaceuticals, and Sichuan Kelun Pharmaceuticals.
What are the primary drivers contributing to the growth of the parenteral nutrition market?
The growth of the parenteral nutrition market is primarily driven by advancements in the supplementation of trace elements in parenteral nutrition, the availability of standardized and commercial parenteral nutrition solutions, and the increasing preference for home-based parenteral nutrition.